Phase 1 Leukaemia Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People who have been diagnosed with acute myeloid leukaemia (AML) that has come back or stopped responding to previous treatment
• People whose AML cells test positive for a specific protein called CLL1
• People who are in reasonably good general health (able to carry out light activity) and are expected to live for more than 12 weeks
• People whose kidneys are working well enough, based on blood tests
• People whose liver is working well enough, based on blood tests measuring bilirubin, ALT, and AST levels
• People whose blood clotting is within an acceptable range, based on INR and aPTT tests
• Women who could become pregnant must have a negative pregnancy test before joining
• People who test negative for donor-specific antibodies (a blood test result below a certain level) (confirm with trial site)
• People who are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

• People who are allergic to any of the drugs used in this trial
• People who have had certain cancer treatments too recently before the first infusion, including: systemic steroids within 3 days; most anti-cancer medicines within 2 weeks; radiation therapy within 4 weeks; donor lymphocyte infusion within 6 weeks; treatment injected into the spinal fluid within 1 week; or CAR-T, CAR-NK, or other gene-modified cell therapies within 6 months
• People who have previously had an allogeneic stem cell transplant (a transplant using cells from another person)
• People who have received a vaccine within 4 weeks before joining, or who are expected to need a vaccine during the study period or within 12 weeks after the last treatment
• People whose leukaemia has spread to the brain or spinal fluid (active central nervous system leukaemia)
• People with a specific type of leukaemia called Acute Promyelocytic Leukaemia (APL)
• People with a history of another cancer, unless that cancer was fully treated more than 5 years ago with no signs of return
• People with an active autoimmune disease (where the immune system attacks the body)
• People with a history of brain or nervous system conditions such as epilepsy, stroke, paralysis, or difficulty speaking
• People with serious heart or blood vessel problems, including certain abnormal heart rhythms, a recent heart attack, heart failure, stroke, or blood pressure that cannot be controlled with medication
• People with an active lung infection, low blood oxygen levels, a blood clot in the lungs, chronic obstructive pulmonary disease, or scarring of the lung tissue
• People with an uncontrolled bacterial, fungal, or viral infection, or who are known to have HIV, active hepatitis B, or active hepatitis C
• People with a history of substance abuse
• People who are still experiencing significant side effects from previous treatments that have not sufficiently recovered
• People who have had major surgery within 4 weeks before the first infusion (not including minor diagnostic procedures such as a biopsy)
• People who are pregnant or breastfeeding
• People whom the trial doctors consider to have medical or personal circumstances that could interfere with safe participation in the trial

Important: Always verify eligibility with the trial site directly before applying.